120 related articles for article (PubMed ID: 9160589)
1. Double-blind pilot trial of desipramine versus fluoxetine in panic patients.
Bystritsky A; Rosen RM; Murphy KJ; Bohn P; Keys SA; Vapnik T
Anxiety; 1994-1995; 1(6):287-90. PubMed ID: 9160589
[No Abstract] [Full Text] [Related]
2. Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients.
Sandor P; Baker B; Irvine J; Dorian P; McKessok D; Mendlowitz S
Depress Anxiety; 1998; 7(2):69-72. PubMed ID: 9614594
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans.
Wong ML; Dong C; Flores DL; Ehrhart-Bornstein M; Bornstein S; Arcos-Burgos M; Licinio J
Am J Psychiatry; 2014 Dec; 171(12):1297-309. PubMed ID: 25220861
[TBL] [Abstract][Full Text] [Related]
4. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients.
Tiffon L; Coplan JD; Papp LA; Gorman JM
J Clin Psychiatry; 1994 Feb; 55(2):66-9. PubMed ID: 8077156
[TBL] [Abstract][Full Text] [Related]
5. A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder.
Sasson Y; Iancu I; Fux M; Taub M; Dannon PN; Zohar J
Eur Neuropsychopharmacol; 1999 Mar; 9(3):191-6. PubMed ID: 10208287
[TBL] [Abstract][Full Text] [Related]
6. Anticholinergic toxic syndrome with venlafaxine-desipramine combination.
Benazzi F
Pharmacopsychiatry; 1998 Jan; 31(1):36-7. PubMed ID: 9524985
[No Abstract] [Full Text] [Related]
7. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.
Fava M; Alpert J; Nierenberg A; Lagomasino I; Sonawalla S; Tedlow J; Worthington J; Baer L; Rosenbaum JF
J Clin Psychopharmacol; 2002 Aug; 22(4):379-87. PubMed ID: 12172337
[TBL] [Abstract][Full Text] [Related]
8. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.
Abolfazli R; Hosseini M; Ghanizadeh A; Ghaleiha A; Tabrizi M; Raznahan M; Golalizadeh M; Akhondzadeh S
Depress Anxiety; 2011 Apr; 28(4):297-302. PubMed ID: 21456039
[TBL] [Abstract][Full Text] [Related]
9. Fluoxetine (prozac) in depresion of adults.
Kocur J; Rydzynski Z; Duszyk S; Gruszczynski W; Trendak W
Homeost Health Dis; 1991; 33(5-6):295. PubMed ID: 18265505
[No Abstract] [Full Text] [Related]
10. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.
Papakostas GI; Petersen T; Denninger JW; Tossani E; Pava JA; Alpert JE; Nierenberg AA; Fava M
J Clin Psychopharmacol; 2004 Oct; 24(5):507-11. PubMed ID: 15349006
[TBL] [Abstract][Full Text] [Related]
11. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA
Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
Wehmeier PM; Kluge M; Maras A; Riemann D; Berger M; Kohnen R; Dittmann RW; Gattaz WF
Pharmacopsychiatry; 2005 Jan; 38(1):13-6. PubMed ID: 15706460
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and acceptability of amineptine versus fluoxetine in major depression.
Dalery J; Rochat C; Peyron E; Bernard G
Int Clin Psychopharmacol; 1997 Jul; 12 Suppl 3():S35-8. PubMed ID: 9347391
[TBL] [Abstract][Full Text] [Related]
14. Predictors of response to amine-specific antidepressants.
Burns RA; Lock T; Edwards DR; Katona CL; Harrison DA; Robertson MM; Nairac B; Abou-Saleh MT
J Affect Disord; 1995 Dec; 35(3):97-106. PubMed ID: 8749837
[TBL] [Abstract][Full Text] [Related]
15. Mirtazapine versus fluoxetine in the treatment of panic disorder.
Ribeiro L; Busnello JV; Kauer-Sant'Anna M; Madruga M; Quevedo J; Busnello EA; Kapczinski F
Braz J Med Biol Res; 2001 Oct; 34(10):1303-7. PubMed ID: 11593305
[TBL] [Abstract][Full Text] [Related]
16. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder.
Papakostas GI; Petersen T; Denninger JW; Montoya HD; Nierenberg AA; Alpert JE; Fava M
Ann Clin Psychiatry; 2003; 15(3-4):187-92. PubMed ID: 14971864
[TBL] [Abstract][Full Text] [Related]
17. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder.
Baker B; Dorian P; Sandor P; Shapiro C; Schell C; Mitchell J; Irvine MJ
J Clin Psychopharmacol; 1997 Feb; 17(1):15-21. PubMed ID: 9004052
[TBL] [Abstract][Full Text] [Related]
18. Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients.
Diaz A; Fouilloux C; Ortiz S
Proc West Pharmacol Soc; 2002; 45():154-5. PubMed ID: 12434564
[No Abstract] [Full Text] [Related]
19. Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression.
Akhondzadeh S; Faraji H; Sadeghi M; Afkham K; Fakhrzadeh H; Kamalipour A
J Clin Pharm Ther; 2003 Oct; 28(5):379-84. PubMed ID: 14632962
[TBL] [Abstract][Full Text] [Related]
20. Fluoxetine dependence in a former amineptine abuser.
Taïeb O; Larroche C; Dutray B; Baubet T; Moro MR
Am J Addict; 2004; 13(5):498-500. PubMed ID: 15764428
[No Abstract] [Full Text] [Related]
[Next] [New Search]
